Site Announcement
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Revenues: | ||||
| Revenues | $ 65,414 | $ 56,425 | $ 206,456 | $ 159,239 |
| Costs and expenses: | ||||
| Cost of revenue | 23,351 | 21,374 | 70,750 | 69,210 |
| Selling, general and administrative | 24,837 | 22,269 | 73,567 | 69,536 |
| Research and development | 32,177 | 29,797 | 94,254 | 90,345 |
| Amortization of intangible assets | 16,458 | 16,539 | 49,327 | 49,064 |
| Total costs and expenses | 96,823 | 89,979 | 287,898 | 278,155 |
| Operating loss | (31,409) | (33,554) | (81,442) | (118,916) |
| Other income (expense), net: | ||||
| Interest income | 2,882 | 2,734 | 8,363 | 10,116 |
| Interest expense | (13,451) | (11,326) | (35,735) | (97,034) |
| Fair value changes of derivative instruments, net | 251 | (38) | (112) | (295) |
| Other income (expense), net | 3,861 | 1,216 | 4,065 | (31,933) |
| Other expense, net | (6,457) | (7,414) | (23,419) | (119,146) |
| Loss before income taxes and investment losses | (37,866) | (40,968) | (104,861) | (238,062) |
| Income tax benefit | 7,310 | 8,051 | 18,700 | 29,012 |
| Net loss before investment losses | (30,556) | (32,917) | (86,161) | (209,050) |
| Loss from investments in investees | (5,000) | (3) | (5,002) | (12) |
| Net income (loss) from continuing operations | (35,556) | (32,920) | (91,163) | (209,062) |
| Income (loss) from discontinued operations, net of tax | (17,978) | 54,551 | (25,635) | 14,639 |
| Net income (loss) | $ (53,534) | $ 21,631 | $ (116,798) | $ (194,423) |
| Basic income (loss) per share: | ||||
| Loss from continuing operations | $ (0.05) | $ (0.04) | $ (0.12) | $ (0.28) |
| Income (loss) from discontinued operations | (0.02) | 0.07 | (0.03) | 0.02 |
| Net income (loss) attributable to common shareholders | (0.07) | 0.03 | (0.16) | (0.26) |
| Diluted income (loss) per share: | ||||
| Loss from continuing operations | (0.05) | (0.04) | (0.12) | (0.28) |
| Income (loss) from discontinued operations | (0.02) | 0.07 | (0.03) | 0.02 |
| Net income (loss) attributable to common shareholders | $ (0.07) | $ 0.03 | $ (0.16) | $ (0.26) |
| Weighted average common shares outstanding, basic | 746,479,131 | 777,154,808 | 753,495,529 | 746,136,135 |
| Weighted average common shares outstanding, diluted | 746,479,131 | 777,154,808 | 753,495,529 | 746,136,135 |
| Product [Member] | ||||
| Revenues: | ||||
| Revenues | $ 41,811 | $ 37,676 | $ 122,795 | $ 113,261 |
| Licensing, Collaboration and Other Revenue [Member] | ||||
| Revenues: | ||||
| Revenues | $ 23,603 | $ 18,749 | $ 83,661 | $ 45,978 |
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations, after deduction of income tax expense (benefit), but before income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. No definition available.
|
| X | ||||||||||
- Definition Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|